Merus Shares Soar 20.7% on Promising Drug Data

Merus (MRUS) shares surged 20.7% in pre-market trading on May 26, 2025, following a series of positive developments that have bolstered investor confidence in the company's prospects.

BMO Capital Markets has raised its price target for Merus to $110, following the release of promising Phase 2 data for its drug candidate petosemtamab. This revision comes after the company's shares were already upgraded to an "outperform" rating on May 24. The positive data has sparked optimism among analysts, with a strong consensus recommendation of 1.24, where 1 is a Strong Buy. This bullish sentiment is further supported by Bank of America, which increased its price target for Merus to $92 from $70 while maintaining a Buy rating on the stock.

Despite the positive outlook, Bank of America had previously decreased their target price for Merus from $73.00 to $70.00 and set a "buy" rating on the stock in a research report on Monday, March 10th. This fluctuation in target prices reflects the dynamic nature of the market and the varying opinions among analysts. However, the overall trend remains positive, with multiple analysts revising their price targets upwards in response to Merus' promising clinical data.